vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Lucky Strike Entertainment Corp (LUCK). Click either name above to swap in a different company.
Lucky Strike Entertainment Corp is the larger business by last-quarter revenue ($306.9M vs $183.1M, roughly 1.7× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -4.1%, a 17.5% gap on every dollar of revenue. On growth, Lucky Strike Entertainment Corp posted the faster year-over-year revenue change (2.3% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $15.2M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 0.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Lucky Strike Entertainment Corporation is an American bowling center, family entertainment center and waterpark operator. It is the largest ten-pin bowling center operator in the world with over 360 centers throughout the United States, Canada and Mexico. The centers have an average of 40 lanes compared to the U.S. bowling center average of 21 lanes.
AMPH vs LUCK — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $306.9M |
| Net Profit | $24.4M | $-12.7M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 10.9% |
| Net Margin | 13.3% | -4.1% |
| Revenue YoY | -1.8% | 2.3% |
| Net Profit YoY | -35.7% | -144.7% |
| EPS (diluted) | $0.51 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $306.9M | ||
| Q3 25 | $191.8M | $292.3M | ||
| Q2 25 | $174.4M | $301.2M | ||
| Q1 25 | $170.5M | $339.9M | ||
| Q4 24 | $186.5M | $300.1M | ||
| Q3 24 | $191.2M | $260.2M | ||
| Q2 24 | $182.4M | — | ||
| Q1 24 | $171.8M | $337.7M |
| Q4 25 | $24.4M | $-12.7M | ||
| Q3 25 | $17.4M | $-13.8M | ||
| Q2 25 | $31.0M | $-74.7M | ||
| Q1 25 | $25.3M | $13.3M | ||
| Q4 24 | $38.0M | $28.3M | ||
| Q3 24 | $40.4M | $23.1M | ||
| Q2 24 | $37.9M | — | ||
| Q1 24 | $43.2M | $23.8M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | 33.1% |
| Q4 25 | 19.4% | 10.9% | ||
| Q3 25 | 13.2% | 9.7% | ||
| Q2 25 | 24.2% | 5.0% | ||
| Q1 25 | 21.9% | 18.3% | ||
| Q4 24 | 24.2% | 15.6% | ||
| Q3 24 | 29.8% | 5.0% | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 27.9% | 21.0% |
| Q4 25 | 13.3% | -4.1% | ||
| Q3 25 | 9.0% | -4.7% | ||
| Q2 25 | 17.8% | -24.8% | ||
| Q1 25 | 14.8% | 3.9% | ||
| Q4 24 | 20.4% | 9.4% | ||
| Q3 24 | 21.1% | 8.9% | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 25.1% | 7.1% |
| Q4 25 | $0.51 | $-0.11 | ||
| Q3 25 | $0.37 | $-0.12 | ||
| Q2 25 | $0.64 | $-0.49 | ||
| Q1 25 | $0.51 | $0.07 | ||
| Q4 24 | $0.74 | $0.16 | ||
| Q3 24 | $0.78 | $0.13 | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $1.8B |
| Stockholders' EquityBook value | $788.8M | $-363.8M |
| Total Assets | $1.6B | $3.3B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $1.8B | ||
| Q3 25 | $608.6M | $1.7B | ||
| Q2 25 | $607.7M | $1.3B | ||
| Q1 25 | $603.9M | $1.3B | ||
| Q4 24 | $601.6M | $1.3B | ||
| Q3 24 | $596.4M | $1.1B | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $1.1B |
| Q4 25 | $788.8M | $-363.8M | ||
| Q3 25 | $776.7M | $-326.3M | ||
| Q2 25 | $757.5M | $-298.7M | ||
| Q1 25 | $751.3M | $-213.7M | ||
| Q4 24 | $732.3M | $-179.7M | ||
| Q3 24 | $727.7M | $-164.3M | ||
| Q2 24 | $713.3M | — | ||
| Q1 24 | $672.4M | $-76.0M |
| Q4 25 | $1.6B | $3.3B | ||
| Q3 25 | $1.7B | $3.2B | ||
| Q2 25 | $1.6B | $3.2B | ||
| Q1 25 | $1.6B | $3.2B | ||
| Q4 24 | $1.6B | $3.2B | ||
| Q3 24 | $1.5B | $3.1B | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | $3.2B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $48.1M |
| Free Cash FlowOCF − Capex | $24.6M | $15.2M |
| FCF MarginFCF / Revenue | 13.4% | 4.9% |
| Capex IntensityCapex / Revenue | 4.5% | 10.7% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $42.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $48.1M | ||
| Q3 25 | $52.6M | $-6.4M | ||
| Q2 25 | $35.6M | $22.5M | ||
| Q1 25 | $35.1M | $86.6M | ||
| Q4 24 | $29.0M | $38.7M | ||
| Q3 24 | $60.0M | $29.4M | ||
| Q2 24 | $69.1M | — | ||
| Q1 24 | $55.3M | $76.9M |
| Q4 25 | $24.6M | $15.2M | ||
| Q3 25 | $47.2M | $-32.3M | ||
| Q2 25 | $25.0M | $-1.1M | ||
| Q1 25 | $24.4M | $61.1M | ||
| Q4 24 | $16.6M | $-11.7M | ||
| Q3 24 | $46.2M | $-12.2M | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | $43.4M |
| Q4 25 | 13.4% | 4.9% | ||
| Q3 25 | 24.6% | -11.1% | ||
| Q2 25 | 14.3% | -0.4% | ||
| Q1 25 | 14.3% | 18.0% | ||
| Q4 24 | 8.9% | -3.9% | ||
| Q3 24 | 24.1% | -4.7% | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | 12.9% |
| Q4 25 | 4.5% | 10.7% | ||
| Q3 25 | 2.8% | 8.9% | ||
| Q2 25 | 6.1% | 7.8% | ||
| Q1 25 | 6.3% | 7.5% | ||
| Q4 24 | 6.7% | 16.8% | ||
| Q3 24 | 7.2% | 16.0% | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | 9.9% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 6.52× | ||
| Q4 24 | 0.76× | 1.37× | ||
| Q3 24 | 1.48× | 1.27× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 3.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
LUCK
| Bowling | $142.9M | 47% |
| Food And Beverage Revenue Stream | $112.4M | 37% |
| Amusement And Other | $51.6M | 17% |
